Daniel F Hayes, MD
Rogel Cancer Center
1500 E. Medical Center Drive, #63122 CCC, SPC 5942
Ann Arbor, MI 48109-5942
Manage Your Profile
About
Dr. Daniel F. Hayes is the Stuart B. Padnos Professor of Breast Cancer Research.at the University of Michigan Rogel Cancer Center.
Dr. Hayes received undergraduate, master’s and medical degrees from Indiana University, followed by a residency in internal medicine at the University of Texas Southwestern Medical School/Health Science Center/Parkland Memorial Hospital and a fellowship in medical oncology at Harvard’s Dana Farber Cancer Institute (DFCI). He has led the breast cancer programs at DFCI (1991-1996), Georgetown University’s Lombardi Cancer Center (1996-2001), and the University of Michigan from 2001-2016.
Dr. Hayes’ research interests are in the field of experimental therapeutics and cancer biomarkers, especially in breast cancer. His work has been particularly focused on development and validation of cancer biomarker tests, such as HER-2, CA15-3, circulating tumor cells and pharmacogenomic markers. He has been instrumental in establishing international guidelines for the use of tumor biomarker tests, including criteria for their clinical utility.
He has served as chair of the SWOG Breast Cancer Translational Medicine Committee, and he was an inaugural member and chaired the American Society of Clinical Oncology (ASCO) Tumor Marker Guidelines Committee. He has been instrumental in the joint ad hoc committees between ASCO and the College of American Pathologists. Dr. Hayes served on the ASCO Board of Directors, and served a 3 year term as President of ASCO from 2016-2018. He is a Fellow of ASCO, a Fellow of the American College of Physicians, a past Komen Scholar, and a member of the Association of American Physicians and of the American Clinical and Climatologic Association. He has been the recipient of the ASCO Gianni Bonadonna Award in breast cancer and the Allen Lichter Visionary Leadership Award in 2021 as well as the Susan G. Komen Brinker Award for Scientific Distinction in Clinical Research in 2023, and has received the Distinguished Alumni Award from the Indiana University Medical School (2024).
Qualifications
-
Clinical Fellow in MedicineHarvard Medical School, Boston, United States
1982 - 1985
-
Fellow in Medical OncologyDana-Farber Cancer Institute, Boston, United States
1982 - 1985
-
Clinical Fellow in MedicineBrigham and Women's Hospital, Boston, United States
1982 - 1985
-
Senior Assistant ResidentParkland Memorial Hospital, Dallas, United States
1981 - 1982
-
Junior Assistant ResidentParkland Memorial Hospital, Dallas, United States
1980 - 1981
-
Intern in MedicineParkland Memorial Hospital, Dallas, United States
1979 - 1980
Center Memberships
-
Center MemberRogel Cancer Center
Research Overview
• Breast Cancer
• Tumor Biomarkers
• Liquid Biopsy/Circulating Tumor Biomarkers
• New Drug Development
Recent Publications
-
Cani AK, Dolce EM, Darga EP, Hu K, Liu C, Robinson D, Wu Y, Paoletti C, Luker GD, Tomlins SA, Udager AM, Henderson NC, Thomas DG, Rae JM, Arul CM, Cobain EF, Hayes DF. Clinical Cancer Research, 2026 Feb 23; 32 (4_Supplement): ps2-07-22-ps2-07-22Journal ArticleAbstract PS2-07-22: Serial, multi-omic, multi-analyte, liquid biopsy monitoring of metastatic lobular breast cancer to detect clinically-relevant heterogeneity and evolution
DOI:10.1158/1557-3265.sabcs25-ps2-07-22 -
Kang IM, Forschmiedt JK, Loch MM, Lew DL, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Rastogi P, Schott AF, Baehner R, Sharma P, Tripathy D, Pusztai L, Hortobagyi GN, Kalinsky K, Henry NL. JAMA Oncol, 2025 Dec 11;Journal ArticleCognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial.
DOI:10.1001/jamaoncol.2025.5220 PMID: PMC12699395 -
Hadley A, Buning G, Henderson NC, Milliron KJ, Hulswit BB, Hipp LE, Pleasant VA, Rae JM, Pilewskie ML, Hayes DF, Henry NL, Merajver SD, Cobain EF. Clinical Cancer Research, 2025 Oct 7; 31 (12_Supplement): p1-05-15-p1-05-15 - p1-05-15-p1-05-15.Journal ArticleA real-world analysis of cancer prevention measures among individuals with hereditary breast and ovarian cancer (HBOC) syndromes and no personal history of malignancy
DOI:10.1158/1557-3265.sabcs24-p1-05-15 -
Janni W, Friedl TWP, Yab TC, Bidard F-C, Cristofanilli M, Hayes DF, Ignatiadis M, Regan MM, Alix-Panabieres C, Barlow WE, Caldas C, Carey LA, Dirix L, Fehm T, Garcia-Saenz JA, Gazzaniga P, Generali D, Gerratana L, Gisbert-Criado R, Jacot W, Jiang Z, Joosse SA, Lianidou E, López López R, Magbanua MJM, Manso L, Mavroudis D, Müller V, Munzone E, Pantel K, Pierga J-Y, Rack B, Riethdorf S, Rugo HS, Sideras K, Sleijfer S, Smerage J, Stebbing J, Terstappen LWMM, Vidal-Martínez J, Wallwiener M, Giridhar KV, Liu MC. Clin Cancer Res, 2025 Mar 18;Journal ArticleClinical validity of repeated circulating tumor cell enumeration as an early treatment monitoring tool for metastatic breast cancer in the PREDICT global pooled analysis.
DOI:10.1158/1078-0432.CCR-24-3108 PMID: 40100138 -
Abdou Y, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Unger JM, Tripathy D, Hortobagyi GN, Pusztai L, Kalinsky K. J Natl Cancer Inst, 2024 Dec 5;Journal ArticleRace and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in the Randomized RxPONDER Trial.
DOI:10.1093/jnci/djae314 PMID: 39656951 -
Mc Laughlin AM, Helland T, Klima F, Koolen SLW, van Schaik RHN, Mathijssen RHJ, Neven P, Swen JJ, Guchelaar HJ, Dalenc F, White-Koning M, Michelet R, Mikus G, Schroth W, Mürdter T, Brauch H, Schwab M, Søiland H, Mellgren G, Thomas F, Kloft C, Hertz DL, Agema BC, Sanchez-Spitman A, Almeida T, Nardin J, Casali-da-Rocha JC, Moo-Puc RE, Rangel-Mendez JA, McMillin G, Hennig EE, Brewczyńska E, Venzon Antunes M, Haufroid V, Thorén L, Madlensky L, Pierce J, Nakaumra Y, Kubo M, Zembutsu H, Bianchi Ximenez JP, Lanchote VL, Rae JM, Hayes DF, Stearns V, Skaar TC, Desta Z, Scott SA, Desnick RJ, Park IH, Woo HI, Lee SY, Fernandez-Santander A, Romero-Lorca A, Villajos AN, Alonso MG, Johansson H, Bonanni B, DeCensi A, Gurney H, Balleine R, Irvin WJ, McLeod HL, Goetz MP, Reid JM, Suman VJ, Areepium N, Charoenchokthavee W, Eccles D, Tapper W, Chowbay B, Khor CC, Hsuen EL, Tfayli A, Zgheib NK, Arellano C. Clinical Pharmacology and Therapeutics, 2024 Sep 1; 116 (3): 690 - 702.Journal ArticleNonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM Cohort
DOI:10.1002/cpt.3238 PMID: 38494911 -
Sparano JA, Crager M, Gray RJ, Tang G, Hoag J, Baehner FL, Shak S, Makower DF, Albain KS, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA, Lively T, Badve SS, Saphner TJ, Whelan TJ, Kaklamani VG, Wolmark N, Sledge GW, Stemmer SM. NEJM Evid, 2024 Aug; 3 (8): EVIDoa2300267Journal ArticleClinical and Genomic Risk for Late Breast Cancer Recurrence and Survival.
DOI:10.1056/EVIDoa2300267 PMID: PMC11730053 -
Kalinsky K, Barlow WE, Pathak HB, Gralow JR, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL, Rastogi P, Schott AF, Shak S, Tripathy D, Hortobagyi GN, Meric-Bernstam F, Sharma P, Pusztai L, Thompson AM, Godwin AK. Journal of Clinical Oncology, 2024 May 31; 42 (16_suppl): 505 - 505.Journal ArticleCorrelation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER).
DOI:10.1200/jco.2024.42.16_suppl.505
Featured News & Stories
